GlobalData on MSN4d
J&J’s Lazcluze/Rybrevant combination obtains European approval to treat NSCLC
The Lazcluze plus Rybrevant combination could challenge AstraZeneca’s standard-of-care Tagrisso in non-small cell lung cancer ...
Cure Today18d
Rybrevant Plus Lazcluze Improves Survival for EGFR+ NSCLC
Rybrevant and Lazcluze combination therapy improves overall survival in EGFR-mutated NSCLC compared to Tagrisso, as shown in the MARIPOSA study. The FDA approved Rybrevant plus Lazcluze in 2024, based ...
The Pharma Letter5d
EC approves added use for J&J’s Lazcluze combo with Rybrevant for lung cancer
The European Commission (EC) has approved a Marketing Authorization (MA) for Lazcluze (lazertinib), in combination with ...
3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever
But a pair of treatments that launched in 2019 are already offsetting Humira's losses. Combined sales of Skyrizi, a psoriasis ...
pharmaphorum7d
J&J says Rybrevant combo has survival edge over Tagrisso
Johnson & Johnson's recently approved combination of Rybrevant and Lazcluze has improved overall survival compared to AstraZeneca's Tagrisso in a head-to-head trial, claiming what could be a key ...
Johnson & Johnson’s rybrevant plus lazcluze improve survival in lung cancer
Johnson & Johnson announced positive topline results for the gold standard endpoint in cancer treatment of overall survival, or OS, from ...
FiercePharma4d
J&J stands by sales growth ambitions—and points to potential Tremfya boon—as Stelara biosimilars take hold
As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...
Nasdaq19d
JNJ's RYBREVANT, LAZCLUZE Show Survival Gains In Lung Cancer; Stock Up
(RTTNews) - Johnson & Johnson (JNJ) on Tuesday announced positive topline results from the Phase 3 MARIPOSA study, highlighting the combination of RYBREVANT and LAZCLUZE as a first-line therapy ...
Nasdaq19d
Johnson & Johnson’s rybrevant plus lazcluze improve survival in lung cancer
Improvement in median OS is expected to exceed one year. The safety profile of rybrevant plus lazcluze was generally consistent with the profiles of the individual treatments. Adverse event rates ...